Nucleix is a liquid biopsy company revolutionizing cancer treatment with earlier disease detection, at a time when intervention can bring the greatest impact for patients. Leveraging PCR-based epigenetics, our pioneering testing approach uses methylation-based identification for early-stage and recurring cancer detection. Our non-invasive EpiCheck® platform delivers highly accurate and sensitive results, all while providing a seamless testing option for patients and the healthcare system. We are building an EpiCheck franchise, beginning with our Bladder EpiCheck testing kit marketed in Europe for bladder cancer recurrence and are advancing a Lung EpiCheck test toward commercialization for high-risk individuals, while advancing additional tests for high-risk diseases. Nucleix has offices in San Diego, California and Rehovot, Israel. For more information, please visit https://www.nucleix.com/.

Privately-held company focusing on the identification and validation of protein biomarkers that can serve as the basis for novel in vitro diagnostic tests. The Company was acquired by bioMerieux, Inc. in April 2018. Achievements included:• Raised equity and debt capital from venture providers to support the research, clinical / product development, and commercialization of NephroCheck® and the company’s Astute140® Meter platform, as well as, the advancement of the company’s product pipeline.• Team member involved in the negotiation of strategic business transactions to expand commercial market for NephroCheck®, such as (i) out-licensing the company’s technology to allow the product to be used on a larger base of diagnostic platforms and (ii) establishing strategic distribution arrangements for Europe and China. • Managed financial and human resources reporting, including all financial statements, accounts payable, accounts receivable, budgeting/forecasting, information technology, facilities, insurance, contract management, payroll, benefits, employee hiring/termination, performance management, compensation, stock option management and corporate legal matters.• Established a wholly-owned European subsidiary to provide a direct commercial presence, as well as support distribution partners. Responsible for all accounting, human resource, legal, tax and regulatory matters.• Collaborated with multiple company constituents, including the Board of Directors, attorneys (US and internationally based), investment bankers and business partners to provide operational analysis, including: operating and capital budget to manage monthly spending; periodic cash flow projections to ensure the company remained in compliance with debt covenants; waterfall calculations to help investors to determine the return on their investment; and human resource tools to ensure that company remained competitive for human capital.

NEXUS Biosystems provided enabling technologies and automated sample management systems to pharmaceutical, biotech, agrichemical and research institutions worldwide. The Company was acquired by Brooks Automation (NASDAQ: BRKS) in 2011. Achievements included:• Developed consolidated operating budget, which reflected multiple product lines and new business initiatives.• Completed the acquisition of Aurora Biotechnologies, by finalizing the negotiation of terms, completing the drafting of all legal documents, and establishing a process to integrate the financial operations of the two companies.• Communicated with the Board of Directors on a variety of accounting matters including revenue recognition, stock option accounting, and business combinations. Supervised the financial reporting, payroll, accounts payable, accounts receivable and information technology functions.• Resolved outstanding financial reporting obligations for the company’s European sales and service subsidiary by working with subsidiary personnel to identify deliverables, establish timelines and drive the team towards completion.• Interviewed and retained an accounting firm to conduct the company’s first-ever independent audit, following discussions with multiple firms.

A non-profit organization dedicated to creating and sustaining the growth of innovative technology and life science businesses in San Diego. EIR's provide coaching and guidance to start-up companies.

A publicly-traded biotechnology company focused on the discovery, development and commercialization of innovative cancer therapeutics. The Company was acquired by Eli Lilly & Company in 2008. Achievements included:∙ Created liquidity for investors by helping negotiate the sale of the company to Eli Lilly & Company. Acquisition completed at a premium of 119% to the company’s then-current trading price.∙ Completed $25 million initial public offering and $25 million private placement transaction, which provided additional capital and expanded the company’s investor base.∙ Lead the transition from a private to a public organization by recruiting experienced staff, establishing financial reporting capabilities to meet SEC requirements, and developing a reporting package for the company’s Audit Committee. Directed the company’s first formal internal control review in compliance with Sarbanes-Oxley Section 404.∙ Facilitated the financial due diligence of a multi-million dollar research collaboration, which contributed over $30 million to the company’s operations in March 2006.∙ Communicated the company’s message to investors, media and the financial community by presenting at conferences and participating on discussion panels focused on the life science industry.∙ Directly managed departments including a finance team of five people, an information technology team of three people and one senior investor/public relations.

Provide professional advice, information and know-how on a variety of operational and financial subjects including: advising company management on technical accounting principles; leading project teams in the timely completion of their Sarbanes-Oxley Section 404 and 302 audits/reviews; and preparing various SEC reports including 10-K and proxy.

A privately-held company developing oncology products based on a patented drug-delivery technology. Responsibilities included: maintaining relationships with investors and the financial community including venture capitalists, lenders and investment bankers; acting as a strategic business partner by providing the CEO, and other managers, key financial information; and developing and negotiating business agreements to support operational objectives. Hired as Vice President, Finance and Business Development and, in April 2001, named Chief Financial Officer, Secretary and Treasurer.

Responsible for the financial and administrative functions of this publicly traded, computational drug-discovery company. Managed the growth of this organization from 40 to 100 employees while revenues increased from $3 million to $15 million. Contributed as a key team member to the Company’s IPO in May 1998 and directed on-going reporting to the Securities and Exchange Commission. Hired as Controller and, in June 1999, promoted to Director of Finance reporting directly to the Chief Executive Officer. In November 1999, DuPont Pharmaceuticals acquired the Company at a premium of 100% to its trading price.

Managed various financial responsibilities for this leading healthcare alliance comprised of approximately 1,700 hospitals and other healthcare organizations. The Company supports its members’ efforts to improve their operational, financial, and clinical performance. The Company provides services such as group purchasing and supply chain management and comparative information resources.

Various audit assignments in the technology, health care and real estate industries